Payment overview · 2025
General Payments
$201.75
10 reported records · 6 companies
Healthcare provider profile · identity verified
John M Watson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · RENO, NV · NPI 1366460347
Verified facts
What the public records show
CMS Open Payments records show John M Watson, MD received $201.75 in general payments during 2025 across 10 reported records.
PFIZER INC. accounted for 30.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 215 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $60.89 | 30.2% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $39.73 | 19.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $35.74 | 17.7% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $22.69 | 11.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.66 | 10.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.04 | 10.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $201.75 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $42.65 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $39.73 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $35.74 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $24.28 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.96 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $22.69 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.66 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.04 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 127 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 70 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
127 | 43 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
70 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
215 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
127 | 43 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1211 | 374 |
| Levothyroxine Sodium | Levothyroxine Sodium | 716 | 214 |
| Losartan Potassium | Losartan Potassium | 696 | 215 |
| Lisinopril | Lisinopril | 531 | 159 |
| Amlodipine Besylate | Amlodipine Besylate | 521 | 169 |
| Omeprazole | Omeprazole | 434 | 139 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 394 | 127 |
| Metformin Hcl Er | Metformin Hcl | 387 | 133 |
| Metformin Hcl | Metformin Hcl | 275 | 87 |
| Tamsulosin Hcl | Tamsulosin Hcl | 274 | 104 |
| Hydrochlorothiazide | Hydrochlorothiazide | 261 | 88 |
| Trazodone Hcl | Trazodone Hcl | 256 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 248 | 79 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 231 | 75 |
| Ozempic | Semaglutide | 215 | 40 |
| Gabapentin | Gabapentin | 181 | 68 |
| Simvastatin | Simvastatin | 181 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 167 | 59 |
| Jardiance | Empagliflozin | 158 | 54 |
| Eliquis | Apixaban | 127 | 43 |
| Allopurinol | Allopurinol | 124 | 41 |
| Montelukast Sodium | Montelukast Sodium | 122 | 40 |
| Potassium Chloride | Potassium Chloride | 121 | 43 |
| Carvedilol | Carvedilol | 118 | 44 |
| Furosemide | Furosemide | 118 | 42 |
| Glimepiride | Glimepiride | 108 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 107 | 39 |
| Fluoxetine Hcl | Fluoxetine Hcl | 105 | 37 |
| Mirtazapine | Mirtazapine | 101 | 29 |
| Celecoxib | Celecoxib | 95 | 36 |
| Trulicity | Dulaglutide | 94 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 91 | 27 |
| Finasteride | Finasteride | 88 | 32 |
| Ezetimibe | Ezetimibe | 85 | 26 |
| Farxiga | Dapagliflozin Propanediol | 85 | 23 |
| Alendronate Sodium | Alendronate Sodium | 83 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 81 | 28 |
| Methylprednisolone | Methylprednisolone | 75 | 52 |
| Spironolactone | Spironolactone | 72 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 70 | 21 |
| Acyclovir | Acyclovir | 67 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | 22 |
| Januvia | Sitagliptin Phosphate | 58 | 17 |
| Sertraline Hcl | Sertraline Hcl | 54 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 17 |
| Valsartan | Valsartan | 50 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 48 | 16 |
| Lovastatin | Lovastatin | 48 | 15 |
| Synthroid | Levothyroxine Sodium | 48 | 14 |
| Xarelto | Rivaroxaban | 48 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 46 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 12 |
| Bupropion Xl | Bupropion Hcl | 43 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 43 | 16 |
| Azelastine Hcl | Azelastine Hcl | 40 | 23 |
| Estradiol | Estradiol | 40 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 38 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 29 |
| Prednisone | Prednisone | 35 | 16 |
| Glipizide | Glipizide | 34 | suppressed |
| Irbesartan | Irbesartan | 34 | 11 |
| Nystatin | Nystatin | 32 | 11 |
| Valacyclovir | Valacyclovir Hcl | 32 | 14 |
| Alprazolam | Alprazolam | 30 | 13 |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Famotidine | Famotidine | 29 | 11 |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Azithromycin | Azithromycin | 26 | 23 |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 15 |
| Sildenafil Citrate | Sildenafil Citrate | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | 11 |
| Pregabalin | Pregabalin | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | 12 |
| Primidone | Primidone | 20 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 20 | suppressed |
| Fluconazole | Fluconazole | 18 | 12 |
| Metronidazole | Metronidazole | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $201.75 · 10 records | PFIZER INC. | ABRYSVO, AREXVY, COMIRNATY, ELIQUIS, Kerendia, NURTEC ODT, PAXLOVID, PREVNAR 20, TRELEGY ELLIPTA, VRAYLAR, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error